first combination DNA vaccine for rabies developed.
Bangalore-based Indian Institute of Science (IISc) and Indian
Immunologicals, Hyderabad have jointly developed the world's
first combination vaccine containing DNA vaccine and a low
of dose of cell culture vaccine. Animal toxicity tests of
the vaccine are conducted at the National Institute of Nutrition,
Hyderabad and the combination vaccine is expected to cost
less than the existing ones in the market.
P N Rangarajan, associate professor, biochemistry department,
IISc has worked on combination rabies vaccine (CRV) for the
past five years. IISc has teamed up with Indian Immunologicals,
which is now conducting various studies to scale up and undertake
commercial production of the vaccine. It may take some time
to launch the product in the market.
for clinical trials is yet to be obtained from Drugs Controller
General of India. The department of biotechnology (DBT) is
funding the current tests under Jai Vignan Vaccine Mission.
rabies vaccine available in the market for veterinary and
humans are cell culture vaccines, which is expensive to manufacture.
But, in most government hospitals, the nerve tissue vaccine
is used for rabies, which has been banned worldwide, informs
programme of the CRV at IISc commenced with the development
of a DNA rabies vaccine (DRV) by taking a gene from the rabies
virus and introducing it into the multiplying bacteria. But
a vaccine produced in this method, was only 50-70 per cent
effective, though the cost of production was less than that
of the cell culture vaccine. Working further on its potency,
the IISc team of scientists found that addition of small
quantity of the modern cell culture vaccine enhances the
potency of DRV and this unique combination.
we aim to do is to bring the world's first vaccine containing
DNA to the market," said Prof. Rangarajan. The principle
works best on both human and veterinary vaccine and has shown
positive results on mice and cattle.
team has already filed an international patent under the
PCT [Patent Cooperative Treaty] and its International Search
Report has confirmed it as a unique vaccine, informed Prof.
Rangarajan. "We now have to file for patents in all PCT countries,
which would take another year."